Feasibility study to characterize price and reimbursement decision-making criteria for the inclusion of new drugs in the Spanish National Health System

//Feasibility study to characterize price and reimbursement decision-making criteria for the inclusion of new drugs in the Spanish National Health System

Feasibility study to characterize price and reimbursement decision-making criteria for the inclusion of new drugs in the Spanish National Health System

We are very pleased to share the first study characterizing the criteria of the Royal Legislative Decree 1/2015 for the reimbursement of new medicines in Spain, performed by an expert panel with broad experience on drug evaluation and decision-making in Spain.

The study, which Omakase is co-author, is published in the International Journal of Technology Assessment in Health Care and is available here: https://www.cambridge.org/core/journals/international-journal-of-technology-assessment-in-health-care/article/feasibility-study-to-characterize-price-and-reimbursement-decisionmaking-criteria-for-the-inclusion-of-new-drugs-in-the-spanish-national-health-system-the-cefiderocol-example/C9217EFB97145ADBA6217B3D51B33BD5

2022-06-22T15:53:52+00:00June 22nd, 2022|Articles|